CU20130072A7 - 1 h-pirazol-5-olato sódico sustituido - Google Patents

1 h-pirazol-5-olato sódico sustituido

Info

Publication number
CU20130072A7
CU20130072A7 CU2013000072A CU20130072A CU20130072A7 CU 20130072 A7 CU20130072 A7 CU 20130072A7 CU 2013000072 A CU2013000072 A CU 2013000072A CU 20130072 A CU20130072 A CU 20130072A CU 20130072 A7 CU20130072 A7 CU 20130072A7
Authority
CU
Cuba
Prior art keywords
pirazol
olato
diseases
substituted sodium
prophylaxis
Prior art date
Application number
CU2013000072A
Other languages
English (en)
Inventor
Hans-Christian Militzer
Jörg Gries
Stefan Koep
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CU20130072A7 publication Critical patent/CU20130072A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)

Abstract

La presente solicitud se refiere a 1-[6-(morfolin-4-il]-4-(1 H-1,2,3-triazol-1-il)-1 H -pirazol-5-olato sódico, a procedimientos para su preparación, su uso para el tratamiento y/o la profilazis de enfermedades como también su uso para la preparación de medicamentos para el tratamiento y/o la profilaxis de enfermedades, especialmente de enfermedades cardiovasculares y hematológicas, de enfermedades renales como también para ayudar a la curación de heridas.
CU2013000072A 2010-11-18 2013-05-16 1 h-pirazol-5-olato sódico sustituido CU20130072A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010044131A DE102010044131A1 (de) 2010-11-18 2010-11-18 Substituiertes Natrium-1H-pyrazol-5-olat
PCT/EP2011/070099 WO2012065967A1 (de) 2010-11-18 2011-11-15 Substítuiertes natrium-1h-pyrazol-5-olat

Publications (1)

Publication Number Publication Date
CU20130072A7 true CU20130072A7 (es) 2013-09-27

Family

ID=44999768

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2013000072A CU20130072A7 (es) 2010-11-18 2013-05-16 1 h-pirazol-5-olato sódico sustituido

Country Status (45)

Country Link
US (2) US8653074B2 (es)
EP (1) EP2640718B8 (es)
JP (1) JP5918779B2 (es)
KR (2) KR101984317B1 (es)
CN (2) CN104650047A (es)
AP (1) AP3429A (es)
AR (1) AR083887A1 (es)
AU (1) AU2011331305B2 (es)
BR (1) BR112013012223B1 (es)
CA (1) CA2818002C (es)
CL (1) CL2013001390A1 (es)
CO (1) CO6741155A2 (es)
CR (1) CR20130196A (es)
CU (1) CU20130072A7 (es)
CY (1) CY1120375T1 (es)
DE (1) DE102010044131A1 (es)
DK (1) DK2640718T3 (es)
DO (1) DOP2013000096A (es)
EA (1) EA023103B1 (es)
EC (1) ECSP13012627A (es)
ES (1) ES2675580T3 (es)
GT (1) GT201300125A (es)
HK (2) HK1188782A1 (es)
HR (1) HRP20180993T1 (es)
HU (1) HUE038024T2 (es)
IL (1) IL226192A (es)
JO (1) JOP20110347B1 (es)
LT (1) LT2640718T (es)
MA (1) MA34671B1 (es)
MX (1) MX347670B (es)
MY (1) MY167219A (es)
NZ (1) NZ610614A (es)
PE (2) PE20180324A1 (es)
PL (1) PL2640718T3 (es)
PT (1) PT2640718T (es)
RS (1) RS57599B1 (es)
SG (1) SG189975A1 (es)
SI (1) SI2640718T1 (es)
TN (1) TN2013000215A1 (es)
TR (1) TR201806652T4 (es)
TW (1) TWI516485B (es)
UA (1) UA112422C2 (es)
UY (1) UY33736A (es)
WO (1) WO2012065967A1 (es)
ZA (1) ZA201304430B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102010044131A1 (de) 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat
AU2013258107B2 (en) * 2012-05-08 2017-06-22 Bayer Pharma Aktiengesellschaft Method for the preparation of triazole compounds
BR112016007588A2 (pt) * 2013-10-17 2017-09-12 Bayer Pharma AG formas de dosagem farmacêutica compreendendo sódio 1-[6- (morfolina-4-il) pirimidina-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato
ES2747234T3 (es) 2014-09-26 2020-03-10 Cleveland Clinic Found Tratamiento y prevención de enfermedades con agentes reductores de TMA y TMAO
CL2015003047A1 (es) * 2015-10-15 2016-06-17 Univ Chile Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina
WO2018149929A1 (en) * 2017-02-16 2018-08-23 Bayer Pharma Aktiengesellschaft Combination of reporter gene assays and transcriptional analysis
EP3888684A1 (en) * 2020-03-31 2021-10-06 Bayer Animal Health GmbH Composition having improved voluntary acceptance

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1519069A (fr) 1966-04-13 1968-03-29 Geigy Ag J R Dérivés du sulfanilamide et leur préparation
US4075003A (en) 1975-12-11 1978-02-21 Eli Lilly And Company Novel herbicidal method utilizing 1,4-diphenyl-3-pyrazolin-5-ones
GR63123B (en) 1975-12-11 1979-09-11 Lilly Co Eli Preparation process of novel 1,4-diphenyl-3-pyrazolin-5-ones
PL103509B1 (pl) 1976-09-20 1979-06-30 Lilly Co Eli Srodek chwastobojczy
US4663327A (en) 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
DE3443308A1 (de) 1984-11-28 1986-05-28 Bayer Ag, 5090 Leverkusen 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel
DE3527157A1 (de) 1985-07-30 1987-02-12 Bayer Ag 1-heteroaryl-4-aryl-pyrazol-derivate
DE4204919A1 (de) 1992-02-19 1993-08-26 Bayer Ag Verfahren zur herstellung von 2-chlor-5-alkylaminomethyl-pyridinen
JPH0735361B2 (ja) * 1993-09-09 1995-04-19 日産化学工業株式会社 ヒドラゾン誘導体およびその製造方法
FR2725988B1 (fr) 1994-10-24 1997-01-24 Roussel Uclaf Nouveaux derives de pyrazolones et pyrazoles acides, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
JPH10306077A (ja) 1997-05-07 1998-11-17 Daiichi Rajio Isotope Kenkyusho:Kk ビピラゾール誘導体並びにこれを有効成分とする医薬および試薬
DE19909237A1 (de) 1999-03-03 2000-09-07 Merck Patent Gmbh Pyrazol-3-on-derivate
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
CA2447593C (en) 2001-05-15 2014-07-08 Ortho-Mcneil Pharmaceutical, Inc. Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
JP4316893B2 (ja) 2001-05-16 2009-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ｓｒｃおよび他のプロテインキナーゼのインヒビター
EP1429761B1 (en) 2001-09-21 2006-11-08 Solvay Pharmaceuticals B.V. Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
ES2295441T3 (es) 2001-12-18 2008-04-16 MERCK & CO., INC. Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato.
WO2003074550A2 (en) 2002-03-01 2003-09-12 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
UY27813A1 (es) * 2002-05-31 2003-12-31 Smithkline Beecham Corp Inhibidores de la peptido-desformilasa
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7652033B2 (en) 2003-03-27 2010-01-26 Emory University HIF-1 inhibitors
US20060194807A1 (en) 2003-04-03 2006-08-31 Cosford Nicholas D P Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
CA2525298A1 (en) 2003-05-01 2004-11-18 Panacea Pharmaceuticals, Inc. Methods of treating ischemic related conditions
CN1842332A (zh) * 2003-06-30 2006-10-04 Hif生物公司 化合物、组合物及方法
US7226941B2 (en) 2003-06-30 2007-06-05 Hif Bio, Inc. Compound for treating angiogenesis
CA2614068A1 (en) 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
DE102008020113A1 (de) 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
KR20070112276A (ko) 2005-03-16 2007-11-22 아벤티스 파마슈티칼스 인크. 중추신경계 약제로서의 디피라졸
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
WO2007121687A1 (fr) 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Dérivés du 4-méthyl-1h-diaryl pyrazole et leur utilisation comme médicaments
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050513A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE102010044131A1 (de) 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat

Also Published As

Publication number Publication date
EP2640718B8 (de) 2018-06-27
DE102010044131A1 (de) 2012-05-24
WO2012065967A1 (de) 2012-05-24
CY1120375T1 (el) 2019-07-10
MX2013004797A (es) 2013-06-28
HK1210776A1 (en) 2016-05-06
ECSP13012627A (es) 2013-07-31
MX347670B (es) 2017-05-03
TW201307328A (zh) 2013-02-16
EP2640718B1 (de) 2018-03-28
KR101984317B1 (ko) 2019-05-30
US20120129857A1 (en) 2012-05-24
NZ610614A (en) 2015-05-29
CO6741155A2 (es) 2013-08-30
DOP2013000096A (es) 2013-06-15
BR112013012223B1 (pt) 2021-06-29
MY167219A (en) 2018-08-14
US20130310381A1 (en) 2013-11-21
AU2011331305A1 (en) 2013-06-06
US9533972B2 (en) 2017-01-03
TR201806652T4 (tr) 2018-06-21
IL226192A0 (en) 2013-07-31
BR112013012223A2 (pt) 2020-03-10
EP2640718A1 (de) 2013-09-25
AR083887A1 (es) 2013-03-27
ZA201304430B (en) 2014-12-23
SG189975A1 (en) 2013-06-28
AP3429A (en) 2015-09-30
CL2013001390A1 (es) 2014-04-04
EA201390703A1 (ru) 2013-12-30
SI2640718T1 (en) 2018-08-31
ES2675580T3 (es) 2018-07-11
HK1188782A1 (en) 2014-05-16
TN2013000215A1 (en) 2014-11-10
DK2640718T3 (da) 2018-07-16
PL2640718T3 (pl) 2018-08-31
KR20180023043A (ko) 2018-03-06
HRP20180993T1 (hr) 2018-08-10
EA023103B1 (ru) 2016-04-29
CN103270031B (zh) 2015-06-17
CA2818002A1 (en) 2012-05-24
TWI516485B (zh) 2016-01-11
LT2640718T (lt) 2018-07-10
PE20180324A1 (es) 2018-02-13
UY33736A (es) 2012-06-29
JP2014500877A (ja) 2014-01-16
IL226192A (en) 2016-06-30
PE20140391A1 (es) 2014-03-29
RS57599B1 (sr) 2018-11-30
CN104650047A (zh) 2015-05-27
AU2011331305B2 (en) 2016-06-02
GT201300125A (es) 2017-07-26
CR20130196A (es) 2013-08-06
PT2640718T (pt) 2018-07-04
US8653074B2 (en) 2014-02-18
JOP20110347B1 (ar) 2021-08-17
MA34671B1 (fr) 2013-11-02
JP5918779B2 (ja) 2016-05-18
CA2818002C (en) 2019-01-15
UA112422C2 (uk) 2016-09-12
KR20130131335A (ko) 2013-12-03
HUE038024T2 (hu) 2018-09-28
CN103270031A (zh) 2013-08-28
AP2013006922A0 (en) 2013-06-30

Similar Documents

Publication Publication Date Title
CU20130072A7 (es) 1 h-pirazol-5-olato sódico sustituido
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
ECSP12012310A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
UY31228A1 (es) Ariloxazoles sustituidos y su uso
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
CO6690816A2 (es) Derivados de quinazolin-4(3h)-ona utilizados como inhibidores de pi3 cinasa
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
ECSP10010494A (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
GT201200164A (es) "nuevos compuestos de espiropiperidina"
EA201600434A1 (ru) Применение производных бензимидазолпролина
CU20090216A7 (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea
HN2011003102A (es) Piperidinas sustituidas
DOP2009000093A (es) Dihidropirazolonas sustituídas para el tratamiento de enfermedades cardiovasculares y hematológicas
PA8845501A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes de curación de heridas
CU23951B1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
DOP2011000211A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematologicas
CU20100181A7 (es) Derivados de (pirazolilcarbonil)imidazolidinonas para el tratamiento de enfermedades retrovirales